ELVElevance Health (ELV) shows mixed signals. It has a solid financial foundation and participates in a growing healthcare market. However, recent performance shows a significant downturn, and valuation metrics like P/E are relatively high compared to its historical average and some industry peers. Technicals suggest a bearish short-term trend.
Elevance Health operates in the expanding healthcare and health insurance sector, benefiting from demographic trends and increasing demand for managed care services. The company's diversified offerings, including pharmacy services and health-related capabilities, position it well within the resilient healthcare industry.
Elevance Health demonstrates consistent revenue and earnings, with a solid balance sheet. However, the current P/E ratio is elevated relative to its past performance and future earnings estimates, and net margins have seen a slight decline. Dividend yield is modest.
The stock has experienced a significant decline over the past 1 month (-24.85%) and 6 months (-31.22%), indicating strong downward momentum. Current technical indicators across multiple timeframes (1m, 5m, 15m, 1h, 2h, 4h, 1d) predominantly signal 'Sell' or 'Neutral', suggesting a prevailing bearish sentiment and a potential for further downside.
| Factor | Score |
|---|---|
| Healthcare & Health Insurance Demand | 85 |
| Managed Care Services Growth | 80 |
| Regulatory Landscape | 60 |
| Digital Health & Innovation | 70 |
| Economic Sensitivity | 70 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 55 |
| Growth | 60 |
| Balance Sheet Health | 70 |
| Cash Flow | 75 |
| Dividends | 60 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 30 |
| Volume Confirmation | 50 |
| Support & Resistance | 40 |
| Oscillators | 30 |
Strong Earnings Beat
Most recent quarterly EPS estimate was $11.97, exceeding the estimate of $11.38 by 5.16%. This indicates strong current profitability.
Attractive P/E Ratio
The trailing P/E ratio is 11.89, which is generally considered attractive and suggests the stock may be undervalued relative to its earnings.
Significant Recent Decline
The stock has experienced a -24.85% decline in the last month and -31.22% over the last 6 months, indicating significant recent downward price momentum.
High Forward P/E
The projected P/E ratio for Q2 2025 is 50.2, which is significantly higher than the trailing P/E, suggesting future earnings expectations may be very optimistic or that the stock is expensive on a forward-looking basis.
September 2025
10
Ex-Dividend Date
September 2025
25
Next Dividend Date
October 2025
16
Next Earnings Date
H: $8.97
A: $5.89
L: $4.47
H: 50.20B
A: 49.18B
L: 48.14B
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.
392.28 USD
The 39 analysts offering 1 year price forecasts for ELV have a max estimate of 556.33 and a min estimate of 310.00.